笔记详情
标题
不良反应描（Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in c
内容
Safety parameters
Adverse events are defined as any untoward medical occurrence in a patient from the beginning of radioimmunotherapy (day 57) up to the follow-up visit 12 months post completion of combined radioimmunotherapy. All adverse events under standard induction chemotherapy and prior to the first administration of cetuximab will be recorded as medical history. Adverse Events will be reported using NCI CTCAE v4.0.
来源
BMC Cancer. 2011; 11: 182.
类别
领域
Cancer/Oncology
关键词
